BMC Immunology (Jul 2008)

The frequency of CD127<sup>low </sup>expressing CD4<sup>+</sup>CD25<sup>high </sup>T regulatory cells is inversely correlated with human T lymphotrophic virus type-1 (HTLV-1) proviral load in HTLV-1-infection and HTLV-1-associated myelopathy/tropical spastic paraparesis

  • Chieia Marco,
  • Sabino Ester C,
  • Nukui Youko,
  • Neto Walter,
  • Brunialti Milena KC,
  • Chapman Joan M,
  • Jordan Kimberley A,
  • Barbosa Hugo,
  • Michaëlsson Jakob,
  • Oliveira Acary,
  • Nixon Douglas F,
  • Kallas Esper G

DOI
https://doi.org/10.1186/1471-2172-9-41
Journal volume & issue
Vol. 9, no. 1
p. 41

Abstract

Read online

Abstract Background CD4+CD25high regulatory T (TReg) cells modulate antigen-specific T cell responses, and can suppress anti-viral immunity. In HTLV-1 infection, a selective decrease in the function of TReg cell mediated HTLV-1-tax inhibition of FOXP3 expression has been described. The purpose of this study was to assess the frequency and phenotype of TReg cells in HTLV-1 asymptomatic carriers and in HTLV-1-associated neurological disease (HAM/TSP) patients, and to correlate with measures of T cell activation. Results We were able to confirm that HTLV-I drives activation, spontaneous IFNγ production, and proliferation of CD4+ T cells. We also observed a significantly lower proportion of CTLA-4+ TReg cells (CD4+CD25high T cells) in subjects with HAM/TSP patients compared to healthy controls. Ki-67 expression was negatively correlated to the frequency of CTLA-4+ TReg cells in HAM/TSP only, although Ki-67 expression was inversely correlated with the percentage of CD127low TReg cells in healthy control subjects. Finally, the proportion of CD127low TReg cells correlated inversely with HTLV-1 proviral load. Conclusion Taken together, the results suggest that TReg cells may be subverted in HAM/TSP patients, which could explain the marked cellular activation, spontaneous cytokine production, and proliferation of CD4+ T cells, in particular those expressing the CD25highCD127low phenotype. TReg cells represent a potential target for therapeutic intervention for patients with HTLV-1-related neurological diseases.